Challenges of urine-based molecular assays for the detection of urothelial cancer

In the issue of Modern Pathology, April 25 2019, Eich and colleagues highlight the relevance of a urine assay called ‘UroSEEK’ as a non-invasive approach for the detection of primary or recurrent urothelial carcinoma of the bladder (UCB). The UROSEEK assay consists of three components; TERTSeqS, UroSeqS, and FastSeqS, which cover molecular alterations in 11 genes that frequently occur in UCB, in addition to aneuploidy (FastSeqS) (1).